Evidence map›Paper›PMID 15476678›Full record

ArticleBiochemical pharmacology2004

Shift in purine/pyrimidine base recognition upon exchanging extracellular domains in P2Y 1/6 chimeric receptors.

Carsten Hoffmann, Kelly Soltysiak, Patrick L West, Kenneth A Jacobson

Abstract read
In one paragraph

Article in Biochemical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. The microglial P2YTranslational neurodegeneration · 2024
    Review
  2. Demystifying P2YJournal of chemical information and modeling · 2017
    Article
  3. Review
  4. Article
  5. Review
  6. Agonists and antagonists for P2 receptors.Novartis Foundation symposium · 2006
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Carsten HoffmannMolecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA.
Kelly Soltysiak
Patrick L West
Kenneth A Jacobson
National Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · US

Funding

PROSTHETIC GROUPS FOR RADIOLABELING OF FUNCTIONALIZED DRUGS AND PEPTIDESZ01DK031116 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$769k
Intramural NIH HHS Z01 DK031116Intramural NIH HHS Z99 DK999999
6 · The paper itself

Abstract

P2Y receptors are G protein-coupled receptors stimulated by extracellular nucleotides. Both the P2Y(1) and the P2Y(6) receptors are preferentially activated by nucleoside 5'-diphosphates, but favor different base moieties. In the case of the P2Y(1) receptor the preferred base is adenine, while the P2Y(6) receptor is activated by uracil nucleotides. To identify potential amino acid domains that interact with the base moiety, we used a chimeric receptor approach, employing the human P2Y(1) receptor as core structure to investigate the role in receptor activation of extracellular loops (ELs) and transmembrane domains (TMs) of the rat P2Y(6) receptor. The chimeric receptors were expressed in COS-7 cells and measured for stimulation of phospholipase C (PLC) induced by the potent P2Y(1) receptor agonist 2-MeSADP or the potent P2Y(6) receptor agonist UDP. Replacement of the N-terminus or EL2 resulted in low ( approximately 50 microM) potency of the agonist 2-MeSADP, thus confirming the importance of EL2 in ligand recognition. Upon replacement of several regions, the potency of the P2Y(1) agonist 2-MeSADP was either 1-2 microM (N-terminus and EL1, or EL1 and EL3) or 72 microM (N-terminus and EL3). Concurrent replacement of three regions (N-terminus, EL1, and EL3) completely precluded activation by 2-MeSADP. Our study identified domains of the P2Y(6) receptor that contribute to receptor activation by UDP and hence seem to be involved in uracil recognition. Upon replacement with extracellular domains of the P2Y(6) receptor sequence we observed a trend toward gain of receptor-induced PLC activation by UDP, for example, in the chimera containing replacements of both the N-terminus and EL1. Exchange of three receptor domains led to a construct with an EC(50) value for UDP of 19 microM and a maximal inositol phosphate accumulation similar to the native P2Y(6) receptor. Within receptor constructs of combined domain exchanges the additional substitution of Tyr(110) by the corresponding Asn from the P2Y(6) receptor showed a significant increase for activation by UDP, but only when combined with the N-terminal domain and TM1. The residue Tyr(110) was identified to play an important role in the recognition of the nucleobase in the P2Y(1) and P2Y(6) receptors.

Indexed as

Amino Acid SequenceAnimalsCOS CellsHumansMolecular Sequence DataProtein Structure, TertiaryPurinesPyrimidinesRatsReceptors, Purinergic P2Receptors, Purinergic P2Y1Recombinant Fusion ProteinsTransfectionP2RY1 protein, humanP2ry1 protein, ratpurinePurinespurinoceptor P2Y6pyrimidinePyrimidinesReceptors, Purinergic P2Receptors, Purinergic P2Y1Recombinant Fusion Proteins

Identifiers

PMID15476678
PMCPMC4371599
OpenAlexW2038947995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.